Exicure, Inc.

107 articles with Exicure, Inc.

• Exicure, Inc. Announces Participation in Upcoming Conferences

  6/3/2021

  Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will participate in the following upcoming conferences: BIO Digital 2021 Format : Corporate update presentation Date : June 10, 2021 Time : 7:00 AM ET

• Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)

  5/13/2021

  Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of Brian C. Bock as the Company’s Chief Financial Officer (CFO) effective immediately.

• Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress

  5/12/2021

  Company Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients With Unmet Medical Needs

• Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress

  3/11/2021

  – Granted two Fast Track designations for cavrotolimod (AST-008) from the U.S. Food and Drug Administration (FDA) in January 2021 and an Orphan Drug Designation in March 2021 – Commenced IND-enabling studies on XCUR-FXN Friedreich’s ataxia in late 2020

• Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University

  3/11/2021

  Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have utilized Exicure’s licensed first generation gold-nanoparticle SNA technology in an investigator-initiated trial for the treatment of glioblastoma (GBM), a deadly form of brain cancer.

• Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors

  3/9/2021

  Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.

• Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod

  3/3/2021

  Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its clinical product candidate, cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma (MCC).

• Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference

  2/23/2021

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021.

• Exicure Announces Participation in 10th Annual SVB Leerink Global Healthcare Conference

  2/9/2021

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in a series of 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Conference, occurring February 24 – 26, 2021.

• Exicure Announces Presentation at 2021 BIO CEO & Investor Digital Conference

  2/2/2021

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that David Giljohann, CEO, will present at the 2021 BIO CEO & Investor Digital Conference, February 16-18, 2021. The presentation will be available to registered conference attendees for on-demand viewing beginning February 15, 2021 at 9:00AM ET

• Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration

  1/11/2021

  Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for its clinical product candidate, cavrotolimod (AST-008), for two development programs:

• Exicure Announces Appointment of James Sulat to Board of Directors

  1/5/2021

  Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of James Sulat to its Board of Directors.

• Exicure Announces Webcast of Presentation at 2021 HC Wainwright BIOCONNECT Conference

  12/29/2020

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021. The presentation will be available for on-demand viewing beginning January 11, 2021 at 6:00 AM EST via the virtual conference link: htt

• Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day

  12/28/2020

  Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, announced that it will host a virtual R&D Day on Thursday, January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure’s neuroscience pipeline, including its lead program for Friedreich’s Ataxia which has progressed into IND-enabling studies.

• Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034

  12/21/2020

  Patents and patent application provide additional coverage for company’s therapeutic for patients with advanced solid tumors

• Exicure to Participate in Upcoming Conferences

  11/16/2020

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in the following conferences during the month of November: 2020 Virtual Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day One-on-one meetings Monday, November 16, 2020 Virtual Fall Investor Summit P

• Exicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress

  11/12/2020

  Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter and nine months ended September 30, 2020 and provided an update on corporate progress. “Exicure has seen growth and clinical and pre-clinical advancement during the third quarter of this year,” said Dr. David Giljo

• Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

  11/9/2020

  Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing proprietary spherical nucleic acid (SNA™) technology, today announced the presentation of updated Phase 1b data from the ongoing Phase 1b/2 clinical trial evaluating intratumoral cavrotolimod

• Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

  10/19/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing proprietary spherical nucleic acid technology, announced an upcoming poster presentation for its intratumoral product candidate, cavrotolimod, at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer, to be held virtually from November 9-14, 2020.

• Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

  10/5/2020

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a presentation at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020.